Forte Biosciences Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St futures climb ahead of this week's megacap earnings
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Wall St futures climb ahead of this week's megacap earnings
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
- AMC Entertainment posts record quarterly revenue and EBITDA in Q2 2026
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight
- AMC Entertainment (AMC) Tops Q2 EPS by 16c
Forte Biosciences (FBRX) Announces Pricing of $40 Million Public Offering of Common Stock at $28.50/sh
October 29, 2020 8:22 AM EDTForte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted to the underwriters a 30-day option to purchase up to an additional 210,526 shares of common stock... More
